Results 81 to 90 of about 691 (170)

Chagas disease in Italy: an update of epidemiological studies. [PDF]

Infez Med, 2023
Antinori S, Giacomelli A, Sabaini F, Casalini G, Ridolfo AL.   +4 more
europepmc   +1 more source

Risk of clinical events in virologically suppressed people with HIV switching to a two-drug regimen vs. remaining on a three-drug regimen: a target trial emulation. [PDF]

EClinicalMedicine
Mussini C, Giacomelli A, Quiros-Roldan E, Mazzotta V, Di Biagio A, De Vito A, Costantini A, D'Ettorre G, Giacometti A, Vergori A, Tavelli A, Malagnino V, Castagna A, Chester J, Antinori A, d'Arminio Monforte A, Cozzi-Lepri A, Icona Foundation Cohort Study for the Icona Foundation Study Group.   +17 more
europepmc   +1 more source

Risk of type 2 diabetes mellitus after treatment with direct-acting antivirals for hepatitis C virus in people with HIV. [PDF]

AIDS
Chalouni M, Torgersen J, Rentsch CT, Van Santen DK, Jarrin I, Klein MB, Young J, Gill MJ, Epstein RL, Linas B, Zangerle R, Surial B, Nemeth J, Touloumi G, Papadopoulos A, Wittkop L, Van Der Valk M, Boyd A, Monforte AD, Puoti M, Logan RW, Rein SM, Miro JM, Berenguer J, Hernán MA, Lodi S.   +25 more
europepmc   +1 more source

Severe viral rash progression prediction and surveillance early warning based on local-global attention and temporal convolutional network. [PDF]

Front Public Health
Li S, Li Z, Mo Y, Qiu B, Ning Z, Ren J, Wang Z, He X.   +7 more
europepmc   +1 more source

Probability of Starting Two-Drug Regimen (2DR) vs. Three-Drug Regimen (3DR) in ART-Naïve and ART-Experienced Person with HIV (PWH) Across the First Wave of COVID-19 Pandemic. [PDF]

Viruses
Vergori A, Gianotti N, Tavelli A, Tincati C, Giacomelli A, Matteini E, Lapadula G, Taramasso L, Sarmati L, D'Arminio Monforte A, Antinori A, Cozzi-Lepri A, On Behalf Of The Icona Foundation Study, ICONA Foundation Study.   +13 more
europepmc   +1 more source

Icona Vs Quadro. Il dualismo visuale dell'Ekphrasis dostoevskiana [PDF]

Kaiak, 2016
Antonina Nocera
doaj  

Mpox in Europe, 2022-2026: A Scoping Review of Viral Clades, Host Determinants of Severity and Antiviral Therapy. [PDF]

Viruses
Sofos F, Pana ZD, Drikakis D.
europepmc   +1 more source

Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians' and nurses' points of view. [PDF]

J Antimicrob Chemother
Cingolani A, Tavelli A, De Benedittis S, Mastrorosa I, Muccini C, Bini T, Carraro A, Compagno M, Mazzitelli M, Guastavigna M, Cernuschi M, Torti C, Antinori A, d'Arminio Monforte A, ICONA Foundation Study group.   +14 more
europepmc   +1 more source

Use of Preventive Measures for Cardiovascular Disease in People With HIV. [PDF]

Open Forum Infect Dis
Jaschinski N, Neesgaard B, Wit F, Van der Valk M, Kowalska J, Ridolfo AL, Günthard HF, Stöckle M, Wallner E, Nowak P, Castagna A, d'Arminio Monforte A, Petoumenos K, Hoy JF, Hosein S, Lundgren J, Garges H, Rogatto F, Young L, Peters L, Mocroft A, Ryom L, RESPOND Study Group .   +22 more
europepmc   +1 more source

Clinical and laboratory predictors of mpox severity and duration: an Italian multicentre cohort study (mpox-Icona). [PDF]

EBioMedicine
Mazzotta V, Nozza S, Lanini S, Moschese D, Tavelli A, Rossotti R, Fusco FM, Biasioli L, Matusali G, Raccagni AR, Mileto D, Maci C, Lapadula G, Di Biagio A, Pipitò L, Tamburrini E, Monforte AD, Castagna A, Antinori A, mpox-Icona study group.   +19 more
europepmc   +1 more source